{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:52Z","timestamp":1791331252810,"version":"4.3.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T00:00:00Z","timestamp":1638576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.canlet.2021.11.032","type":"journal-article","created":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T10:26:35Z","timestamp":1638613595000},"page":"273-283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia"],"prefix":"10.1016","volume":"526","author":[{"given":"Kazuharu","family":"Kamachi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5034-3699","authenticated-orcid":false,"given":"Hiroshi","family":"Ureshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kurahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Fukuda-Kurahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1490-9923","authenticated-orcid":false,"given":"Yoshihiro","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9036-4865","authenticated-orcid":false,"given":"Hideyo","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3405-7817","authenticated-orcid":false,"given":"Toshikazu","family":"Ushijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3124-5206","authenticated-orcid":false,"given":"Seiji","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.canlet.2021.11.032_bib1","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2021.11.032_bib2","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.canlet.2021.11.032_bib3","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.canlet.2021.11.032_bib4","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study","volume":"31","author":"Hochhaus","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.canlet.2021.11.032_bib5","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2021.11.032_bib6","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/S2352-3026(19)30235-2","article-title":"Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial","volume":"7","author":"Kimura","year":"2020","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.canlet.2021.11.032_bib7","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/1878-0261.12744","article-title":"The DNA methylation landscape of hematological malignancies: an update","volume":"14","author":"Blecua","year":"2020","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2021.11.032_bib8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2016-04-708560","article-title":"Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy","volume":"129","author":"Kim","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.canlet.2021.11.032_bib9","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1038\/bcj.2017.36","article-title":"Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia","volume":"7","author":"Togasaki","year":"2017","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.canlet.2021.11.032_bib10","doi-asserted-by":"crossref","first-page":"7091","DOI":"10.1038\/ncomms8091","article-title":"Dissecting the role of aberrant DNA methylation in human leukaemia","volume":"6","author":"Amabile","year":"2015","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.canlet.2021.11.032_bib11","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2016.143","article-title":"Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia","volume":"30","author":"Heller","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.canlet.2021.11.032_bib12","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cncr.22470","article-title":"Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia","volume":"109","author":"Oki","year":"2007","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.canlet.2021.11.032_bib13","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/ajh.25939","article-title":"Phase I\/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia","volume":"95","author":"Abaza","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"12","key":"10.1016\/j.canlet.2021.11.032_bib14","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: stemming the tide of persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.canlet.2021.11.032_bib15","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment","volume":"118","author":"Chu","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.canlet.2021.11.032_bib16","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.canlet.2021.11.032_bib17","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.canlet.2021.11.032_bib18","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.stem.2009.08.016","article-title":"DNA methyltransferase 1 is essential for and uniquely regulates hematopoietic stem and progenitor cells","volume":"5","author":"Trowbridge","year":"2009","journal-title":"Cell Stem Cell"},{"issue":"7280","key":"10.1016\/j.canlet.2021.11.032_bib19","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature08683","article-title":"DNMT1 maintains progenitor function in self-renewing somatic tissue","volume":"463","author":"Sen","year":"2010","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.canlet.2021.11.032_bib20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41375-018-0192-z","article-title":"Dnmt1 links BCR-ABLp210 to epigenetic tumor stem cell priming in myeloid leukemia","volume":"33","author":"Vicente-Due\u00f1as","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2021.11.032_bib21","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3389\/fcell.2019.00136","article-title":"Epigenetic reprogramming and emerging epigenetic therapies in CML","volume":"7","author":"Bugler","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.canlet.2021.11.032_bib22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13148-019-0709-y","article-title":"Novel prodrugs of decitabine with greater metabolic stability and less toxicity","volume":"11","author":"Hattori","year":"2019","journal-title":"Clin. Epigenet."},{"issue":"7","key":"10.1016\/j.canlet.2021.11.032_bib23","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1182\/blood.2019003084","article-title":"Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100","volume":"136","author":"Watanabe","year":"2020","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.canlet.2021.11.032_bib24","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1158\/1535-7163.MCT-20-1125","article-title":"Silylation of deoxynucleotide analog yields an orally available drug with anti-leukemia effects","volume":"20","author":"Ureshino","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"issue":"5","key":"10.1016\/j.canlet.2021.11.032_bib25","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1600-0609.2007.00835.x","article-title":"Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn","volume":"78","author":"Ito","year":"2007","journal-title":"Eur. J. Haematol."},{"issue":"12","key":"10.1016\/j.canlet.2021.11.032_bib26","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","article-title":"NS-187, a potent and selective dual Bcr-Abl\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia","volume":"106","author":"Kimura","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.canlet.2021.11.032_bib27","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/leu.2012.258","article-title":"C\/EBP\u03b2 promotes BCR-ABL-mediated myeloid expansion and leukemic stem cell exhaustion","volume":"27","author":"Hayashi","year":"2013","journal-title":"Leukemia"},{"issue":"1\u20132","key":"10.1016\/j.canlet.2021.11.032_bib28","first-page":"70","article-title":"ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays","volume":"347","author":"Hu","year":"2009","journal-title":"J. Immunol. Methods"},{"issue":"3","key":"10.1016\/j.canlet.2021.11.032_bib29","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"issue":"11","key":"10.1016\/j.canlet.2021.11.032_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079044","article-title":"Comparison of methods for quantification of global DNA methylation in human cells and tissues","volume":"8","author":"Lisanti","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2021.11.032_bib31","doi-asserted-by":"crossref","unstructured":"Valletta S, et al. ASXL1 mutation correction by CRISPR\/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts. Oncotarget 6(42):44061\u201344071.","DOI":"10.18632\/oncotarget.6392"},{"issue":"8","key":"10.1016\/j.canlet.2021.11.032_bib32","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"13","key":"10.1016\/j.canlet.2021.11.032_bib33","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1182\/blood-2011-03-341073","article-title":"SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia","volume":"118","author":"Esposito","year":"2011","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.canlet.2021.11.032_bib34","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1073\/pnas.0602402103","article-title":"Loss of p53 impedes the antileukemic response to BCR-ABL inhibition","volume":"103","author":"Wendel","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"56","key":"10.1016\/j.canlet.2021.11.032_bib35","doi-asserted-by":"crossref","first-page":"9063","DOI":"10.1038\/sj.onc.1207229","article-title":"Mechanisms of apoptosis induction by nucleoside analogs","volume":"22","author":"Sampath","year":"2003","journal-title":"Oncogene"},{"issue":"15","key":"10.1016\/j.canlet.2021.11.032_bib36","doi-asserted-by":"crossref","first-page":"15161","DOI":"10.1074\/jbc.M311703200","article-title":"5-aza-2\u2019-deoxycytidine activates the p53\/p21Waf1\/Cip1 pathway to inhibit cell proliferation","volume":"279","author":"Zhu","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.canlet.2021.11.032_bib37","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nrm2395","article-title":"Transcriptional control of human p53-regulated genes","volume":"9","author":"Riley","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.canlet.2021.11.032_bib38","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrc2657","article-title":"P21 in cancer: intricate networks and multiple activities","volume":"9","author":"Abbas","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"5334","key":"10.1016\/j.canlet.2021.11.032_bib39","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1126\/science.277.5334.1996","article-title":"Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21(WAF1)","volume":"277","author":"Chuang","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.canlet.2021.11.032_bib40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.leukres.2017.03.014","article-title":"DNA methyltransferase 1 mediated aberrant methylation and silencing of SHP-1 gene in chronic myelogenous leukemia cells","volume":"58","author":"Li","year":"2017","journal-title":"Leuk. Res."},{"issue":"8","key":"10.1016\/j.canlet.2021.11.032_bib41","doi-asserted-by":"crossref","first-page":"13156","DOI":"10.1002\/jcb.28590","article-title":"The effect of decitabine on the expression and methylation of the PPP1CA, BTG2, and PTEN in association with changes in miR-125b, miR-17, and miR-181b in NALM6 cell line","volume":"120","author":"Vafadar","year":"2019","journal-title":"J. Cell. Biochem."},{"issue":"9","key":"10.1016\/j.canlet.2021.11.032_bib42","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1158\/0008-5472.CAN-09-3219","article-title":"YPEL3, a p53-regulated gene that induces cellular senescence","volume":"70","author":"Kelley","year":"2010","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.canlet.2021.11.032_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044979","article-title":"Latexin is down-regulated in hematopoietic malignancies and restoration of expression inhibits lymphoma growth","volume":"7","author":"Liu","year":"2012","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.canlet.2021.11.032_bib44","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.3390\/ijms19113437","article-title":"Selenium-binding protein 1 in human health and disease","volume":"19","author":"Elhodaky","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.canlet.2021.11.032_bib45","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1182\/blood-2008-06-163246","article-title":"Aberrant DNA methylation is a dominant mechanism in MDS progression to AML","volume":"113","author":"Jiang","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.canlet.2021.11.032_bib46","doi-asserted-by":"crossref","first-page":"6985","DOI":"10.1128\/MCB.16.12.6985","article-title":"Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1","volume":"16","author":"Jiao","year":"1996","journal-title":"Mol. Cell Biol."},{"issue":"10","key":"10.1016\/j.canlet.2021.11.032_bib47","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.443","article-title":"Latexin sensitizes leukemogenic cells to gammairradiation-induced cell-cycle arrest and cell death through Rps3 pathway","volume":"5","author":"You","year":"2014","journal-title":"Cell Death Dis."},{"issue":"298","key":"10.1016\/j.canlet.2021.11.032_bib48","doi-asserted-by":"crossref","first-page":"298ra119","DOI":"10.1126\/scitranslmed.aab1740","article-title":"Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling","volume":"7","author":"Riether","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"20","key":"10.1016\/j.canlet.2021.11.032_bib49","doi-asserted-by":"crossref","first-page":"6254","DOI":"10.1158\/1078-0432.CCR-17-0235","article-title":"Inactivation of receptor tyrosine kinases reverts aberrant DNA methylation in acute myeloid leukemia","volume":"23","author":"Shen","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.canlet.2021.11.032_bib50","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1182\/blood.V97.5.1172","article-title":"Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia","volume":"97","author":"Mizuno","year":"2001","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.canlet.2021.11.032_bib51","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/1535-7163.MCT-20-0336","article-title":"HLA polymorphisms are associated with treatment-free remission following discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"20","author":"Ureshino","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"issue":"7046","key":"10.1016\/j.canlet.2021.11.032_bib52","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","article-title":"Dynamics of chronic myeloid leukaemia","volume":"435","author":"Michor","year":"2005","journal-title":"Nature"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521006078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521006078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:02:09Z","timestamp":1759593729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383521006078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":52,"alternative-id":["S0304383521006078"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2021.11.032","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2021.11.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}